Skip to main content

Table 6 OS and PFS (IP group)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

 

Median OS (months)

Median PFS (months)

Protein Expression

Low

High

P-value

Low

High

P-value

 ERCC1

20.2

8.6

0.114

20.2

3.9

0.045

 COX2

15.4

8.6

0.106

5.1

2.9

0.362

 Tubulin B3

5.4

10.6

0.349

4.9

3.9

0.419

 CD4

8.6

3.6

0.946

4.9

2.8

0.81

 CD8

8.6

15.4

0.919

4.9

3.9

0.924

SNPs

        

 MDR1 C3435T

CC

TT

CT

P-value

CC

TT

CT

P-value

 

13.5

15.4

8.2

0.318

8.5

4.9

2.8

0.374

 MDR1 G2677 T

GG

TT

GT

 

GG

TT

GT

 
 

8.2

3.6

15.4

0.104

3.9

2.8

12

0.041

 ERCC1C8092A

AA

CC

CA

 

AA

CC

CA

 
 

3.6

8.6

15.4

0.14

0.9

3.9

5.1

0.008

 ERCC1 N118 N

CC

TT

CT

 

CC

TT

CT

 
 

8.2

10.6

8.5

0.394

5.1

6.4

3.9

0.195